PubAg

Main content area

Comparative evaluation of a novel, moderately hypofractionated radiation protocol in 56 dogs with symptomatic intracranial neoplasia

Author:
Schwarz, Philip, Meier, Valeria, Soukup, Alena, Drees, Randi, Besserer, Jürgen, Beckmann, Katrin, Roos, Malgorzata, Rohrer Bley, Carla
Source:
Journal of veterinary internal medicine 2018 v.32 no.6 pp. 2013-2020
ISSN:
0891-6640
Subject:
brain neoplasms, dogs, observational studies, poisoning, protocols, radiotherapy, statistical analysis
Abstract:
Background: Use of strongly hypofractionated radiation treatments in dogs with intracranial neoplasia did not improve outcomes and yielded increased rates of toxicosis. Objectives: To evaluate safety and efficacy of a new, moderately hypofractionated radiation protocol of 10 × 4 Gy compared to a standard protocol. Animals: Convenience sample of 56 client‐owned dogs with primary symptomatic brain tumors. Methods: Retrospective observational study. Twenty‐six dogs were assigned to the control standard protocol of 20 × 2.5 Gy (group A) and 30 dogs to the new protocol of 10 × 4 Gy (group B), assigned on owners' informed consent. Statistical analysis was conducted under the “as treated” regime, using Kaplan‐Meier and Cox‐regression analysis. Treatment was delivered with technically advanced image‐guided radiation therapy. The 2 treatment groups were compared in terms of outcome and signs of toxicosis. Results: Overall progression‐free interval (PFI) and overall survival (OS) time were favorable, with 663 (95%CI: 497;828) and 637 (95%CI: 403;870) days, respectively. We found no significant difference between the two groups: PFI for dogs in group A vs B was 608 (95%CI: 437;779) days and mean (median not reached) 863 (95%CI: 644;1083) days, respectively (P = .89), and OS for dogs in group A vs B 610 (95%CI: 404;816) and mean (median not reached) 796 (95%CI: 586;1007) days (P = .83). Conclusion and Clinical Importance: In conclusion, 10 × 4 Gy is a safe and efficient protocol for treatment of primary intracranial neoplasia and future dose escalation can be considered.
Agid:
6241774